NCCR AntiResist panel discussion
Antibiotic development is a notoriously complex process, with multiple scientific, regulatory, legal, financial and commercial obstacles to be considered before patients can access any successful new antibiotic. Disperazol Pharma’s CEO, Dr. Michael Graz will join Prof. Dr. Urs Jenal from NCCR AntiResist, Dr. Silke Alt from INCATE and Prof. Kevin Outterson from CARB-X to share insights about the unique challenges of […]
